Breast Cancer Clinical Trial
A Study of SGN-B7H4V in Advanced Solid Tumors
This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease.
Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic).
This study will have three parts. Parts A and B of the study will find out how much SGN-B7H4V should be given to participants. Part C will use the dose found in Parts A and B to find out how safe SGN-B7H4V is and if it works to treat solid tumor cancers.
Participants must have one of the following histologically or cytologically confirmed locally advanced unresectable or metastatic solid tumor types:
High-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer
HER2-negative, HR positive breast cancer
Triple-negative breast cancer (TNBC)
Non-small cell lung cancer (Squamous cell carcinoma [SqCC], Adenocarcinoma [AC])
Cholangiocarcinoma or gallbladder carcinoma
Adenoid cystic carcinoma (ACC) of the head and neck
Parts A and B: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, and, in the judgement of the investigator, should have no appropriate SOC therapeutic option
Part C: Participants must have disease that is relapsed or refractory or be intolerant to SOC therapies, unless contraindicated
Tumor tissue is required for enrollment.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Measurable disease per RECIST version 1.1 at baseline
History of another malignancy within 3 years before the first dose of study drug. Any evidence of residual disease from a previously diagnosed malignancy. Exceptions are malignancies with a negligible risk of metastasis or death.
Known active central nervous system metastases. Participants with previously treated brain metastases may participate provided they:
are clinically stable for at least 4 weeks prior to study entry after brain metastasis treatment
have no new or enlarging brain metastases
and are off corticosteroids prescribed for symptoms associated with brain metastases for at least 7 days prior to the first dose of study treatment.
Previous receipt of an MMAE-containing agent or an agent targeting B7-H4
Pre-existing neuropathy â‰¥ Grade 2 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0
Corneal disease or injury requiring treatment or active monitoring
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 17 Locations for this study
Celebration Florida, 34747, United States More Info
Houston Texas, 77030, United States More Info
Ottawa Ontario, K1H 8, Canada More Info
Berlin Other, 10117, Germany More Info
Barcelona Other, 08035, Spain More Info
Madrid Other, 28050, Spain More Info
London Other, W1G 6, United Kingdom More Info
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.